The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients

• Status: Unknown status
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Testing the effect of providing an antidepressant and anxiety-type escitalopram for patients with glioblastoma on patient's quality of life including the effect of treatment on mood and cognition during treatment.Two subgroups will fill questionnaires :

• Questionnaire mini mental state exam (mmse) which is the maximum score of 30. A score of below 24 indicates a flaw in the level of dementia

• Questionnaire depression / mood PHQ9P(Pa t i e n t H e a l t h Qu e s t i o n n a i r e
• 9)

• The M. D. Anderson Symptom Inventory (MDASI)

• Evaluation of the hospital situation awareness (clinical assessment and questionnaire)

• Cognitive assessment which will be carried out by the Department neuropsychological and include:

• Executive function (Stroop)

• Abstract Reasoning (similarities)

• -Auditory and Spatial Attention (Digit span, Spatial span) visual memory and remembering Literature

• Memory function - visual and auditory (ROCF, RAVLT)

• Language function: Naming and verbal fluency

• Mindstreems Neurotrax

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tel-Aviv Sourasky Medical Center
• Treatments: Citalopram; Dexetimide

Criteria

Inclusion Criteria:* men and women

• Aged 18-80

• who signed an informed consent form

• patients that underwent biopsy or resection of brain glioblastoma.

• KPS≥70

• Patients that are stable in terms of seizures who take only one antiepileptic drug

Exclusion Criteria:

• Patients who suffered from depression within five years,

• Patients treated with antidepressants

• Are not able to answer the questionnaires because of an inability to communicate

• Patients treated with inhibitors (MAOI) such as: nialamide , isocarboxazid , iproniazid, phenerzine, tranylcypromine

• Patients who suffer from epilepsy.

• Patients who suffer from Parkinson's

• Patients who suffer from cardiac dysfunction or heart attack recently.

• Patients with eye problems in expanding pupils - can result in the development of glaucoma and closed angle.

• Severe renal dysfunction. (creatinine clearance <30 mL / min). , Creatinine less than 1.5 times the upper limit of normal or end-stage renal disease

• Hepatic insufficiency -bilirubin General> 1.5 times the upper limit of normal, Hepatic Enzymes less than 2.5 times upper limit of normal

• Pregnant women

• a score of less than 24 test The mini-mental state examination (MMSE)

• allergy to any component of the drug- Talc, croscarmellose sodium, Microcrystalline Cellulose silicified, Magnesium stearate, Hypromellose, Macrogol 400, Titanium Dioxide